

## Enantioconvergent Synthesis of a Promising HMG Co-A Reductase Inhibitor NK-104 from Both Enantiomers of Epichlorohydrin

Seiichi Takano,\* Takashi Kamikubo, Takumichi Sugihara, Mikio Suzuki,† and Kunio Ogasawara

Pharmaceutical Institute, Tohoku University, Aobayama, Sendai 980, Japan

(Received in UK 5 January 1993)

**Abstract:** An enantioconvergent synthesis of (+)-NK-104 (3), a promising HMG Co-A reductase inhibitor, has been developed from both enantiomers of epichlorohydrin.

Fungal metabolites such as compactin (1) and mevillin (2) and their derivatives have been shown to be highly effective low-density lipoprotein (LDL) cholesterol lowering agents through their ability to inhibit 3-hydroxy-3-methylglutaryl coenzyme A (HMG-Co-A) reductase, the rate-limiting enzyme in the biosynthesis of cholesterol, and are used for treatment of hypercholesterolaemia.<sup>1</sup> Since it has been found that their biological activity depends largely on the  $\beta$ -hydroxy- $\delta$ -lactone subunit, a number of unnatural compounds bearing this essential subunit have been prepared<sup>2</sup> and among these (+)-NK-104 (3) was reported to be a promising product by exhibiting 10 fold more activity than the representative products from the fungal metabolites<sup>3</sup> (Figure 1). Synthesis of 3, however, is not an easy task owing to the presence of *E*-olefin conjugated to the quinoline ring which makes introduction of the requisite  $\beta$ -hydroxy- $\delta$ -lactone subunit more difficult. We report here an enantioconvergent synthesis of optically pure (+)-NK-104<sup>4</sup> (3) utilizing both (*R*)- and (*S*)-enantiomers of epichlorohydrin<sup>5</sup> (7).





Figure 1


We first transformed the known ester<sup>6</sup> (4) into the phenyl sulfide (6) in an excellent overall yield (>95%) by reduction with lithium aluminum hydride followed by treating the resulting alcohol (5) with diphenyl disulfide and tri-*n*-butylphosphine<sup>7</sup> (Scheme 1). The sulfide (6), thus obtained, was then reacted with the epoxide<sup>8</sup> (9), prepared from (*S*)-epichlorohydrin [(*S*)-7] in two steps *via* the chlorohydrin (8), in the presence of *n*-butyllithium<sup>8</sup> to give the secondary alcohol (10) in 41% yield (83% based on consumed 6) as an inseparable diastereomeric mixture at the benzylic carbogenic center with some recovery of the sulfide (6) (~40%). After removal of the trimethylsilyl group of 10 on brief exposure to methanolic potassium carbonate,<sup>9</sup> the resulting terminal acetylene (11) (94%) was stirred with copper(II) chloride in methanol under an atmosphere of carbon monoxide in the presence of a catalytic amount of palladium(II) chloride to furnish the methyl ester (12) in 67% yield by carbomethoxylation.<sup>8,10,11</sup> Partial hydrogenation of 12 on Lindlar catalyst yielded the *Z*-olefin (13) which gave the  $\alpha,\beta$ -unsaturated  $\delta$ -lactone (14) in 92% overall yield on refluxing in toluene in the presence of pyridinium *p*-toluenesulfonate. To install the requisite *E*-double bond,<sup>8</sup> the sulfide (14) was first treated with *m*-chloroperbenzoic acid to give the sulfoxide (15). On thermolysis with



Scheme 1

Reagents and conditions: a) LiAlH<sub>4</sub>, THF, 0 °C – room temp.; b) phSSph, *n*-Bu<sub>3</sub>P, pyridine, room temp.

calcium carbonate in refluxing toluene,<sup>8,12 15 15</sup> afforded the single product (16), mp 168–168.5 °C,  $[\alpha]_D^{29}$  –57.84 (c 1.49, CHCl<sub>3</sub>), having the requisite *E*-olefin bond in 96% overall yield from the sulfide (14) (Scheme 2).




Scheme 2

Reagents and conditions: a) trimethylsilylacetylene, *n*-BuLi, then BF<sub>3</sub>·OEt<sub>2</sub>, then (*S*)-7, THF, –78 °C (25 min), –30 °C (18 h); b) KOH, THF, 0 °C, 4 h; c) 6, *n*-BuLi, then 9, THF, –78 °C (1.5 h), –20 °C (10 h); d) K<sub>2</sub>CO<sub>3</sub>, MeOH, room temp., 9 h; e) PdCl<sub>2</sub> (cat.), CuCl<sub>2</sub>, NaOAc, CO, MeOH, room temp., 3 h; f) H<sub>2</sub>, Lindlar cat., MeOH, room temp., 25 h, then PPTS (cat.), toluene, reflux, 1.5 h; g) *m*-CPBA, CH<sub>2</sub>Cl<sub>2</sub>, –78 °C, 1 h, –40 °C, 30 min, then Me<sub>2</sub>S; h) CaCO<sub>3</sub>, toluene, reflux, 30 min.

On the other hand, the sulfide (6) was treated directly with (*R*)-epichlorohydrin [(*R*)-7] in the presence *tert.* butyllithium to give the crude chlorohydrin (17) with some recovery of the sulfide (6) (~40%). Crude 17 was then treated with potassium hydroxide to give the epoxide (18) in 49% overall yield (78% yield based on consumed 6) as a diastereomeric mixture at the benzylic stereogenic center. On reaction with lithium acetylide ethylenediamine complex in DMSO,<sup>13</sup> 18 furnished the terminal acetylene (11) in quantitative yield. This compound could also be transformed into the unsaturated  $\delta$ -lactone (16) in a comparable overall yield by following the established route including the palladium catalyzed carbomethoxylation as shown in Scheme 2. Attempts to obtain the ester (12) directly by treating 18 with methyl lithiopropionate,<sup>14</sup> however, failed even in the presence of boron trifluoride<sup>15</sup> (Scheme 3).


Having obtained the common key intermediate (12) bearing the requisite *E*-olefinic bond convergently from both (*S*)- and (*R*)-enantiomers of epichlorohydrin (7), we next carried out the introduction of the  $\beta$ -hydroxy group on the  $\delta$ -lactone. Since we have established an efficient two-step method for the stereospecific introduction of a  $\beta$ -hydroxy group on a  $\delta$ -lactone system via an epoxide precursor starting from an  $\alpha,\beta$ -unsaturated  $\delta$ -lactone,<sup>8,11,14,16</sup> this was applied to 16 with a slight modification of using a different



Scheme 3

**Reagents and conditions:** a) (i) **6**, *t*-BuLi, then (*R*)-**7**, THF,  $-78\text{ }^{\circ}\text{C}$ , 1 h; (ii) KOH, THF, room temp., 3.5 h; b)  $\text{HC}\equiv\text{CLi}$  ( $\text{CH}_2\text{NH}_2$ )<sub>2</sub>, DMSO, room temp., 30 min; c)  $\text{PdCl}_2$  (cat.),  $\text{CuCl}_2$ , NaOAc, CO, MeOH, room temp., 3 h.

solvent system. Thus, treatment of **16** with an excess (3 equiv.) of 30% hydrogen peroxide and 4N NaOH (5 equiv.) in a 4:1 mixture of methanol and dichloromethane allowed chemo- and stereospecific epoxidation at the lactone double bond to afford the  $\alpha,\beta$ -epoxy lactone (**19**), mp  $170\text{--}171\text{ }^{\circ}\text{C}$ ,  $[\alpha]_{\text{D}}^{28} +43.15$  (*c* 1.13,  $\text{CHCl}_3$ ), in 81% yield as a single stereoisomer. The stereochemistry of **19** could readily be assigned as shown by  $^1\text{H}$ -nmr spectral comparison with those of the related materials<sup>8,11,14,16</sup> which indicated that the hydroperoxide ion was introduced specifically from the stereoelectronically favored<sup>17</sup> *anti*-face to the  $\delta$ -substituent. The following conversion of **19** into (+)-NK-104 (**3**) further confirmed the stereochemistry of the epoxy bond. To avoid solvolytic cleavage of the lactone ring under the reductive cleavage<sup>8,11,14,16</sup> of the epoxide bond, the selenolate complex was generated in THF in place of alcoholic solvents which were employed in the original procedure.<sup>18</sup> Thus, the epoxide (**19**) was treated with the complex, generated in THF in the same reaction flask by treating diphenyl diselenide with sodium borohydride in the presence of a catalytic amount of acetic acid, to afford NK-104 (**3**), mp  $138\text{--}139\text{ }^{\circ}\text{C}$ ,  $[\alpha]_{\text{D}}^{32} +8.84$  (*c* 0.92,  $\text{CHCl}_3$ ) [authentic material<sup>3</sup>: mp  $136\text{--}139\text{ }^{\circ}\text{C}$ ,  $[\alpha]_{\text{D}}^{20} +9.0$  (*c* 1.0,  $\text{CHCl}_3$ )], in 61% yield. Optical and diastereomeric purities of the product were confirmed by hplc analysis using chiral columns [Chiralpack AS and Nucleosil 50-5; *i*-PrOH-hexane (1:9 v/v)] and (+)-**1** obtained was shown to be 97.8% ee and free of diastereomers (Scheme 4).



Scheme 4

**Reagents and conditions:** a) 30%  $\text{H}_2\text{O}_2$ , 4N NaOH, MeOH- $\text{CH}_2\text{Cl}_2$  (4:1),  $0\text{ }^{\circ}\text{C}$ , 40 min; b) phSeSeph,  $\text{NaBH}_4$ , THF,  $40\text{ }^{\circ}\text{C}$ , 10 min, then AcOH (cat.),  $0\text{ }^{\circ}\text{C}$ , then **19**, 20 min.

In conclusion, although the present synthesis of (+)-NK-104 (3) has still to be improved at the coupling stage between the non-chiral and the chiral epoxide segments, it has produced the optically pure material enantioconvergently from both (*R*)- and (*S*)-enantiomers of epichlorohydrin whose large scale production has been established.<sup>19</sup>

#### References and Notes

- † Central Research Laboratory, Nissan Co. Ltd., Funabashi, Japan.
1. For reviews: Endō, A. *J. Med. Chem.* **1985**, *28*, 401; Vega, L.; Grundy, S. *J. Am. Med. Assoc.* **1987**, *257*, 33; Grundy, S. M. *New Engl. J. Med.* **1988**, *319*, 24.
  2. Stokker, G. E.; Hoffman, W. F.; Alberts, A. W.; Cragoe, E. J. Jr.; Deana, A. A.; Gilfillan, J. L.; Huff, J. W.; Novello, F. C.; Prugh, J. D.; Smith, R. L.; Willard, A. K. *J. Med. Chem.* **1985**, *28*, 347; Roth, B. D.; Sliskovic, D. R.; Trivedi, B. K. *Annu. Rep. Med. Chem.* **1989**, *24*, 147; Roth, B. D.; Boxan, T. M. A.; Blankley, C. J.; Chucolowski, A. M.; Creger, P. L.; Crewswell, M. W.; Ferguson, E.; Newton, R. S.; O'Brien, P.; Picard, J.; Roack, W. H.; Sekerke, C. S.; Sliskovic, D. R.; Wilson, M. W. *J. Med. Chem.* **1991**, *34*, 463.
  3. Iwasaki, H.; Suzuki, M.; Yanagawa, H.; Fujikawa, Y.; Kitahara, M. Abstract Paper, 111th Annual Congress of Pharm. Soc. Japan, April, Tokyo, 1991, 29V, 3-042; Abstract Paper, XIth International Symposium on Drugs Affecting Lipid Metabolism, Florence, May, 1992.
  4. Quite recently, an interesting enantioselective synthesis of (+)-NK-104 (3) has been reported by employing a chiral auxiliary strategy, see: Minami, T.; Hiyama, T. *Tetrahedron Lett.* **1992**, *33*, 7525. See also: Reddy, G. B.; Minami, T.; Hiyama, T. *J. Org. Chem.* **1991**, *56*, 5752.
  5. Both enantiomers having optical purity of >98% ee were obtained from DAISO, Osaka, Japan.
  6. Fujikawa, Y.; Suzuki, M.; Iwasaki, H.; Sakashita, M. Japan Kokai, 1989, H1-279866.
  7. Nakagawa, I.; Hata, T. *Tetrahedron Lett.* **1975**, 1409; Nakagawa, I.; Aki, K.; Hata, T. *J. Chem. Soc., Perkin Trans. 1* **1983**, 1315.
  8. Takano, S.; Kamikubo, T.; Sugihara, T.; Ogasawara, K. *Tetrahedron: Asymmetry* **1992**, *3*, 853.
  9. Wenders, P. A.; McKinney, J. A.; Mukai, C. *J. Am. Chem. Soc.* **1990**, *112*, 5369; Suffert, J. *Tetrahedron Lett.* **1990**, *31*, 7437.
  10. Tsuji, J.; Takahashi, M.; Takahashi, T. *Tetrahedron Lett.* **1980**, *21*, 849.
  11. Takano, S.; Setoh, M.; Ogasawara, K. *Tetrahedron: Asymmetry* **1992**, *3*, 533.
  12. Trost, B. M.; Salzman, T. N. *J. Am. Chem. Soc.* **1973**, *95*, 6840.
  13. cf. Takano, S.; Sekiguchi, Y.; Sato, N.; Ogasawara, K. *Synthesis* **1987**, 139.
  14. Takano, S.; Shimazaki, Y.; Moriya, M.; Ogasawara, K. *Chem. Lett.* **1990**, 1177; Takano, S.; Shimazaki, Y.; Iwabuchi, Y.; Ogasawara, K. *Tetrahedron Lett.* **1990**, *30*, 3619.
  15. Yamaguchi, M.; Hirao, I. *Tetrahedron Lett.* **1983**, *24*, 391; Nicolaou, K. C.; Skokotas, G.; Maligres, P.; Zuccarello, Z.; Sweiger, E. J.; Toshima, K.; Wendeborn, S. *Angew. Chem. Int. Ed. Engl.* **1989**, *28*, 1272.
  16. Takano, S.; Shimazaki, Y.; Sekiguchi, Y.; Ogasawara, K. *Synthesis* **1989**, 539.
  17. Deslongchamps, P. 'Stereolectronic Effects in Organic Chemistry', Pergamon, Oxford, 1983, p. 209.
  18. Miyashita, M.; Suzuki, T.; Yoshikoshi, A. *Tetrahedron Lett.* **1987**, *28*, 4293; Miyashita, M.; Hoshino, M.; Suzuki, T.; Yoshikoshi, A. *Chem. Lett.* **1988**, 507.
  19. Kasai, N.; Tsujimura, K.; Unoura, K.; Suzuki, T. *J. Ind. Microbiol.* **1992**, *9*, 97; Commercially available from DAISO Co. Ltd., Osaka, Japan.